Who is sponsoring NCT03288662?

NCT03288662 is sponsored by Military Hospital 103.

What drugs are being tested in NCT03288662?

Interventions in NCT03288662: CT and histopathological classification.

Is NCT03288662 still recruiting?

NCT03288662 is currently completed. Last updated 20 September 2017.

Last reviewed 2017-09-20 · How we verify

NCT03288662

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Relationship Between Computed Tomography Manifestation and Histopathological Classification of Thymic Epithelial Tumors

Completed NA Last updated 20 September 2017

What this trial tests

NA trial testing CT and histopathological classification in Thymoma in 2 participants. Completed in 31 July 2017.

Timeline

1 October 2013

Primary endpoint
1 July 2017

31 July 2017

Quick facts

Lead sponsor	Military Hospital 103
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	2
Start date	1 October 2013
Primary completion	1 July 2017
Estimated completion	31 July 2017

Drugs / interventions tested

CT and histopathological classification

Conditions studied

Thymoma — all drugs for Thymoma →

Sponsor

Military Hospital 103

Who can join

Adults 21 to 71, any sex, with Thymoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

the World Health Organization (WHO) has proposed a classification of histopathological thymic tumor and it significance in prognosis. Chest computed tomography (CT) is the most common method to evaluate thymic epithelial tumors before operation. Therefore, the question is to predict the histopathological type of thymic epithelial tumors before surgery based on CT-scan images , to help determine treatment strategy and prognosis. In Vietnam, there are no published literature on this issue.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Thymoma

Currently open trials in the same condition.

NCT06730308 — Glucocorticoids Combined With Concurrent Chemoradiotherapy for Unresectable Thymoma · Phase 2 · recruiting
NCT06692062 — Hypofractionated Radiotherapy for Thymic Epithelial Tumors · NA · recruiting
NCT06029621 — Robot-assisted vs VATS for Thymoma · NA · recruiting
NCT06301945 — Artificial Intelligence Prediction Tool in Thymic Epithelial Tumors · recruiting
NCT05682742 — Clinical Investigation of the da Vinci Surgical System · NA · active not recruiting

Other Military Hospital 103 trials

Trials by the same sponsor.

NCT07532694 — Diode Laser-Assisted Periodontal Therapy in Kidney Transplant Recipients · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03288662 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Military Hospital 103
Last refreshed: 20 September 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03288662.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing